Polyrizon enters into manufacturing pact for CTM supply of PL-14 allergy blocker

The company states: “Polyrizon (PLRZ) Ltd. announces the signing of a manufacturing agreement with Eurofins CDMO Amatsiaquitaine S.A.S, a leading European-based Good Manufacturing Practice manufacturer. This collaboration will supply Clinical Trial Material for Polyrizon’s PL-14 allergy blocker, in preparation for a clinical trial that is expected to commence in 2025. With this agreement, Polyrizon secures a reliable and compliant manufacturing source for the PL-14 clinical trial. The trial aims to evaluate the safety and efficacy of PL-14 as an allergy blocker, advancing Polyrizon’s mission to address allergy-related health issues through unique nasal sprays. The manufacturing site is set to support the CTM needs for Polyrizon’s planned 2025 trial, offering high-quality and compliant development programs in line with USA and European regulatory standards.”